Tiziana announces development plans for foralumab
11 January 2016 | By Victoria White
The company will first be evaluating foralumab in two clinical indications: graft vs host disease; and ulcerative colitis...
List view / Grid view
11 January 2016 | By Victoria White
The company will first be evaluating foralumab in two clinical indications: graft vs host disease; and ulcerative colitis...
12 September 2014 | By Tiziana Life Sciences
Tiziana Life Sciences announces the appointment of Professor Roberto Pellicciari to the Company’s Scientific Advisory Board and as a consultant to the Company...
30 June 2014 | By Tiziana Life Sciences
Tiziana Life Sciences announces that it has entered into an exclusive license agreement with TTFactor S.r.l...